UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions

Annals of oncology, 2003-09, Vol.14 (9), p.1430-1437

2003

Volltextzugriff (PDF)

Disposition of Glucosinolates and Sulforaphane in Humans After Ingestion of Steamed and Fresh Broccoli

Nutrition and cancer, 2000-01, Vol.38 (2), p.168-178

2000

Volltextzugriff (PDF)

A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity

Cancer chemotherapy and pharmacology, 2013-11, Vol.72 (5), p.1073-1078

2013

Volltextzugriff (PDF)

Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle

Journal of clinical oncology, 2005-09, Vol.23 (25), p.6107-6116

2005

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Antiviral Effects of Hypericin, a Derivative of St. John's Wort Plant, in Patients with Chronic Hepatitis C Virus Infection

Antimicrobial Agents and Chemotherapy, 2001-02, Vol.45 (2), p.517-524

2001

Volltextzugriff (PDF)

Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations

Oncogene, 2008-05, Vol.27 (22), p.3201-3210

2008

Volltextzugriff (PDF)

ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES

Journal of liposome research, 2002, Vol.12 (1-2), p.165-172

2002

Volltextzugriff (PDF)

Phase I study of the PARP inhibitor ABT-888 (veliparib) and pegylated liposomal doxorubicin (PLD) in recurrent ovarian (ov) and breast (br) cancers

Gynecologic oncology, 2012-03, Vol.125, p.S22-S22

2012

Volltextzugriff (PDF)

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

International journal of radiation oncology, biology, physics, 2004-03, Vol.58 (3), p.862-870

2004

Volltextzugriff (PDF)

Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer

Gynecologic oncology, 2006-12, Vol.103 (3), p.783-792

2006

Volltextzugriff (PDF)

Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells

The Journal of biological chemistry, 2003-09, Vol.278 (36), p.33714-33723

2003

Volltextzugriff (PDF)

Intravital observation of Plasmodium berghei sporozoite infection of the liver

PLoS biology, 2005-06, Vol.3 (6), p.e192-e192

2005

Volltextzugriff (PDF)

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

Journal of clinical oncology, 1994-03, Vol.12 (3), p.553-559

1994

Volltextzugriff (PDF)

Hypericin as an inactivator of infectious viruses in blood components

Transfusion (Philadelphia, PA), 1995-05, Vol.35 (5), p.392-400

1995

Volltextzugriff (PDF)

Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines

Clinical cancer research, 2003-03, Vol.9 (3), p.1145-1154

2003

Volltextzugriff (PDF)

Phase I Clinical and Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B, in Solid Tumors

Clinical cancer research, 2004-02, Vol.10 (4), p.1289-1298

2004

Volltextzugriff (PDF)

Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer

Clinical cancer research, 1998-07, Vol.4 (7), p.1679-1688

1998

Volltextzugriff (PDF)

Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study

Clinical cancer research, 1997-08, Vol.3 (8), p.1245-1252

1997

Volltextzugriff (PDF)

7000 ORAL A phase I/II study to determine the feasibility and efficacy of the triple combination of Oblimersen (OBL), Abraxane (ABX), and Temozolomide (TMZ) in metastatic melanoma

European journal of cancer supplements, 2007, Vol.5 (4), p.395-395

2007

Volltextzugriff (PDF)

Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan

Clinical cancer research, 1998-03, Vol.4 (3), p.545-557

1998

Volltextzugriff (PDF)

Pharmacokinetics of the Cardioprotector ADR-529 (ICRF-187) in Escalating Doses Combined With Fixed-Dose Doxorubicin

JNCI : Journal of the National Cancer Institute, 1992-11, Vol.84 (22), p.1725-1730

1992

Volltextzugriff (PDF)

A randomized, double-blind placebo-controlled phase II study of FOLFOX with or without GDC-0449 (vismodegib) in patients with advanced gastric and gastroesophageal junction carcinoma (NCI 8376)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS173-TPS173

2011

Volltextzugriff (PDF)

Select forms of tumor cell apoptosis induce dendritic cell maturation

Journal of leukocyte biology, 2005-03, Vol.77 (3), p.361-368

2005

Volltextzugriff (PDF)

Chlorambucil pharmacokinetics and DNA binding in chronic lymphocytic leukemia lymphocytes

Cancer research (Chicago, Ill.), 1989-02, Vol.49 (3), p.554-559

1989

Volltextzugriff (PDF)

Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.5064-5064

2010

Volltextzugriff (PDF)

1 – 25 von 197

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(175)
Mit Volltextzugriff
(158)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(101)
Life Sciences & Biomedicine
(95)
Humans
(91)
Oncology
(47)
Biological And Medical Sciences
(41)
Female
(41)
Medical Sciences
(38)
Animals
(31)
Middle Aged
(30)
Male
(28)
Adult
(27)
Biochemistry & Molecular Biology
(26)
Pharmacology. Drug Treatments
(25)
Aged
(23)
Antineoplastic Agents
(19)
Mice
(14)
Chromatography, High Pressure Liquid
(13)
Multidisciplinary Sciences
(13)
Science & Technology - Other Topics
(13)
Cell Biology
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions

Disposition of Glucosinolates and Sulforaphane in Humans After Ingestion of Steamed and Fresh Broccoli

A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity

Proteasome Inhibition With Bortezomib (PS-341): A Phase I Study With Pharmacodynamic End Points Using a Day 1 and Day 4 Schedule in a 14-Day Cycle

Pharmacokinetics, Safety, and Antiviral Effects of Hypericin, a Derivative of St. John's Wort Plant, in Patients with Chronic Hepatitis C Virus Infection

Epidermal growth factor receptor activation in prostate cancer by three novel missense mutations

ROLE OF COMPLEMENT ACTIVATION IN HYPERSENSITIVITY REACTIONS TO DOXIL AND HYNIC PEG LIPOSOMES: EXPERIMENTAL AND CLINICAL STUDIES

Phase I study of the PARP inhibitor ABT-888 (veliparib) and pegylated liposomal doxorubicin (PLD) in recurrent ovarian (ov) and breast (br) cancers

Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated

Proceedings of a GOG workshop on intraperitoneal therapy for ovarian cancer

Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells

Intravital observation of Plasmodium berghei sporozoite infection of the liver

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

Hypericin as an inactivator of infectious viruses in blood components

Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines

Phase I Clinical and Pharmacokinetic Study of BMS-247550, a Novel Derivative of Epothilone B, in Solid Tumors

Initial clinical evaluation of radiolabeled MX-DTPA humanized BrE-3 antibody in patients with advanced breast cancer

Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study

7000 ORAL A phase I/II study to determine the feasibility and efficacy of the triple combination of Oblimersen (OBL), Abraxane (ABX), and Temozolomide (TMZ) in metastatic melanoma

Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan

Pharmacokinetics of the Cardioprotector ADR-529 (ICRF-187) in Escalating Doses Combined With Fixed-Dose Doxorubicin

A randomized, double-blind placebo-controlled phase II study of FOLFOX with or without GDC-0449 (vismodegib) in patients with advanced gastric and gastroesophageal junction carcinoma (NCI 8376)

Select forms of tumor cell apoptosis induce dendritic cell maturation

Chlorambucil pharmacokinetics and DNA binding in chronic lymphocytic leukemia lymphocytes

Pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) given alone and with bevacizumab (B) in patients with recurrent epithelial ovarian cancer (rEOC)

Suchergebnisse filtern